The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18496 ↗At a glance
Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Sebastiaan Ten Bokkel Huinink and 17 co-authors. Institution: Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands. Major MEDLINE topics: Crohn Disease, Ileum, Cecum. Cited 2 times so far (Crossref); 40 references. The full text is freely available (open access, CC BY-NC 4.0).
Abstract (original language)
Background
The impact of prophylactic medication following ileocecal resection (ICR) for Crohn's disease (CD) merits further elucidation. Prophylactic medication following ileocecal resection (ICR) is recommended in patients with Crohn’s disease (CD), particularly in patients at increased risk of recurrence, but the impact on long‐term outcomes needs to be further elucidated.
Aim
To evaluate the effect of postoperative prophylactic medication on long‐term prognosis.
Methods
A retrospective cohort study was performed in patients with CD who underwent primary ICR between 2000‐2020 in the Netherlands. Patients were divided into two groups: postoperative prophylactic medication [< 12 weeks following ICR] versus no postoperative prophylactic medication. Outcomes were surgical recurrence [re‐resection for CD], severe endoscopic recurrence [modified Rutgeerts score (mRS) ≥ i3] and endoscopic or radiologic recurrence [mRS ≥ i2b or radiologic recurrence]. Inverse probability of treatment weighting [IPTW] method was used to adjust for confounding and selection bias. Survival and association between postoperative prophylactic medication and outcomes were assessed with Kaplan‐Meier analyses and Cox proportional hazard models.
Results
807 patients underwent ICR (median follow‐up 5.0 years); 36% received postoperative prophylactic medication. Surgical, severe endoscopic and endoscopic or radiologic recurrence rates were significantly lower in those who received prophylactic medication ( p = 0.01; p < 0.01; p < 0.01). IPTW analysis showed a lower risk of severe endoscopic and endoscopic or radiologic recurrence in patients treated with postoperative prophylactic medication (aOR 0.64; 95% CI 0.43–0.97; aOR 0.65; 95% CI 0.47–0.91), which also was identified as a protective factor for severe endoscopic (aHR 0.5; 95% CI 0.4–0.6) and endoscopic or radiologic recurrence (aHR 0.6, 95% CI 0.5–0.7) in multivariable analysis after correction for confounding factors. A comparable protective effect of postoperative prophylactic medication was sustained in patients who underwent ileocolonoscopy
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Gastroenterology and Hepatology, Erasmus University Medical Center Rotterdam, Rotterdam, the Netherlands.
- Department of Biostatistics, Erasmus Medical Center, Rotterdam, the Netherlands.
- Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands.
- Division of Gastroenterology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- Gastroenterology Department, Hôpital Saint-Louis-APHP, Université Paris Cité, Paris, France.
- Department of Gastroenterology and Hepatology, Radboud Medical Center, Nijmegen, the Netherlands.
ORCID profiles: Sebastiaan Ten Bokkel Huinink, Michiel T J Bak, Matthieu Allez, Frank Hoentjen
Cite
APA
Ten Bokkel Huinink, S., Bak, M. T. J., Beelen, E. M. J., Erler, N. S., Silverberg, M. S., Allez, M., Hoentjen, F., Bodelier, A. G. L., Dijkstra, G., Romberg-Camps, M., de Boer, N. K. H., Stassen, L. P. S., van der Meulen-de Jong, A. E., West, R. L., van der Woude, C. J., van Ruler, O., de Vries, A. C., & Dutch Initiative on Crohn and Colitis (ICC) (2025). The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18496
Vancouver
Ten Bokkel Huinink S, Bak MTJ, Beelen EMJ, Erler NS, Silverberg MS, Allez M, et al. The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18496
BibTeX
@article{TenBokkelHuinink2025,
author = {Ten Bokkel Huinink, Sebastiaan and Bak, Michiel T J and Beelen, Evelien M J and Erler, Nicole S and Silverberg, Mark S and Allez, Matthieu and Hoentjen, Frank and Bodelier, Alexander G L and Dijkstra, Gerard and Romberg-Camps, Marielle and de Boer, Nanne K H and Stassen, Laurents P S and van der Meulen-de Jong, Andrea E and West, Rachel L and van der Woude, C Janneke and van Ruler, Oddeke and de Vries, Annemarie C and Dutch Initiative on Crohn and Colitis (ICC), Dutch Initiative on Crohn and Colitis (ICC)},
title = {The Impact of Postoperative Prophylactic Medication on Long‐Term Surgical, Severe Endoscopic and Endoscopic or Radiologic Recurrence Following Primary Ileocecal Resection in Patients With Crohn's Disease},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18496}
}
EUVIMED